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A large fraction of human tumours carries mutations in the p53 gene. p53 plays a central role in controlling cell cycle
checkpoint regulation, DNA repair, transcription, and apoptosis upon genotoxic stress. Lack of p53 function impairs these
cellular processes, and this may be the basis of resistance to chemotherapeutic regimens. By virtue of the involvement of
DNA mismatch repair in modulating cytotoxic pathways in response to DNA damaging agents, we investigated the effects of
loss of Pms2 on the sensitivity to a panel of widely used anticancer agents in E1A/Ha-Ras-transformed p53-null mouse
ﬁbroblasts either proﬁcient or deﬁcient in Pms2. We report that lack of the Pms2 gene is associated with an increased
sensitivity, ranging from 2–6-fold, to some types of anticancer agents including the topoisomerase II poisons doxorubicin,
etoposide and mitoxantrone, the platinum compounds cisplatin and oxaliplatin, the taxanes docetaxel and paclitaxel, and the
antimetabolite gemcitabine. In contrast, no change in sensitivity was found after treatment with 5-ﬂuorouracil. Cell cycle
analysis revealed that both, Pms2-deﬁcient and -proﬁcient cells, retain the ability to arrest at the G2/M upon cisplatin
treatment. The data indicate that the concomitant loss of Pms2 function chemosensitises p53-deﬁcient cells to some types of
anticancer agents, that Pms2 positively modulates cell survival by mechanisms independent of p53, and that increased
cytotoxicity is paralleled by increased apoptosis. Tumour-targeted functional inhibition of Pms2 may be a valuable strategy for
increasing the efﬁcacy of anticancer agents in the treatment of p53-mutant cancers.
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The tumour suppressor gene p53 plays a central role in controlling
cell cycle checkpoint regulation, DNA repair, transcription, and
apoptosis upon genotoxic stress. p53 is one of the most frequently
mutated genes in human cancers and plays a critical role in the
regulation of cell cycle and apoptosis (Levine, 1997). A number
of studies have suggested that loss of p53 function may be a major
reason underlying failure to respond to chemotherapy (Ferreira et
al, 1999). Evidence for this notion is emerging from studies of
established human cancer cell lines and from knockout mice
models.
DNA mismatch repair (MMR) proteins play an important role
in the maintenance of genomic stability since it corrects replicative
mismatches that escape DNA polymerase proofreading. Loss of
MMR results in genomic instability characterised by small insertion
and deletion mutations in repetitive sequences throughout the
genome. As well as being involved in carcinogenesis, loss of the
MMR activity is of concern with respect to the use of chemother-
apeutic agents to treat established tumours. Loss of MMR has been
reported to cause resistance to some types of anticancer agents
including cisplatin (Fink et al, 1996) and the topoisomerase II
poisons (Fedier et al, 2001). Interestingly, loss of MLH1 function
has recently been reported to result in an increased sensitivity to
cisplatin in p53-mutated human colorectal adenocarcinoma cells
(Vikhanskaya et al, 1999; Lin et al, 2001). However, the cell lines
used in these previous studies were not truly isogenic, since in
order to restore MMR activity, a whole copy of chromosome 3
carrying a wild-type copy of MLH1 was inserted into the
HCT116 cells. Thus, it is conceivable that the differences in cispla-
tin sensitivity observed in these cell lines could have been due to
one of the many genes on the inserted chromosome other than
the wild-type copy of the missing MMR gene. So far no informa-
tion is available on the effect of loss of PMS2, another MMR gene,
to chemotherapeutic agents in p53-deﬁcient cells.
Using transformed primary ﬁbroblasts established from E1A/Ha-
Ras-transfected knockout mice, we report here that p53-deﬁcient
cells are sensitised to some anticancer agents by the additional loss
of the Pms2 gene, indicating that Pms2 positively regulates cell
survival by a p53-independent mechanism. Tumour-targeted func-
tional inhibition of Pms2 may thus be an adjunct to anticancer
agents in the treatment of p53-mutant cancers.
MATERIALS AND METHODS
Cell lines
The Pms2
7/7/p53
7/7 and Pms2
+/+/p53
7/7 cell lines, established
from E1A/Ha-Ras-transformed knockout mice primary ﬁbroblasts,
were generously provided by Dr PM Glazer (Zeng et al, 2000).
These primary ﬁbroblasts have been produced by breeding mice
heterozygous for Pms2 to either wild-type or p53-null mice, and
then by intercrossing progeny animals to generate mice either
wild-type or null for Pms2 in a p53-nullizygous background. The
cells were maintained in DMEM medium supplemented with
2m ML -glutamine (Life Technologies, Basel, Switzerland), 10%
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penicillin/streptomycin (100 U ml
71/100 mgm l
71, Life Technolo-
gies) at 378C in a humidiﬁed atmosphere containing 5% carbon
dioxide. The Pms2
7/7/p53
7/7 cells as well as the Pms2
+/+/p53
7/7
cells form deﬁned individual colonies when seeded sparsely on
standard culture dishes. All the cell lines tested negative for
contamination with Mycoplasma spp.
Reagents
The following drugs were generous gifts: docetaxel (Aventis,
Zurich, Switzerland), cisplatin, etoposide and paclitaxel (Bristol-
Myers Squipp, Baar, Switzerland), mitoxantrone (Lederle, Zug,
Switzerland), doxorubicin (Pharmacia & Upjohn, Dubendorf, Swit-
zerland), 5-ﬂuorouracil (Roche, Reinach, Switzerland), gemcitabine
(Eli Lilly, Vernier, Switzerland), and oxaliplatin (Sanoﬁ-Synthelabo,
Meyrin, Switzerland).
Antiproliferative and cytotoxicity assays
Cisplatin, oxaliplatin, doxorubicin, mitoxantrone and 5-ﬂuoroura-
cil were dissolved immediately before use in 0.9% NaCl solution.
Etoposide and paclitaxel were prepared in DMSO, whereas doce-
taxel was dissolved in methanol. The ﬁnal concentration of
DMSO or methanol in the cultures was 50.1% at all drug concen-
trations and in controls. Previous experiments (data not shown)
have shown that neither 0.1% DMSO nor 0.1% methanol affects
the viability or growth of these cell lines.
The antiproliferative effect in response to drug treatment was
determined by the colorimetric MTT-assay (Mosmann, 1983).
Brieﬂy, cells growing in the log phase were harvested by brief tryp-
sinisation and washed once with medium containing 10% foetal
calf serum. Using 96 well plates, 1000 cells were plated 24 h prior
to incubation with or without the drug for 72 h at 378C in a humi-
diﬁed atmosphere containing 5% carbon dioxide. A volume of
20 ml MTT in PBS to a ﬁnal concentration of 0.5 mg ml
71 was
added, followed by incubation at 378C for 4 h, aspiration of the
medium, and addition of 200 ml DMSO. Optical density was
measured by the Emax microplate reader E9336 (Molecular Devices,
Clearwater, MN, USA) at 540 nm setting the value of the cell lines
in medium to 1.0 (control) and the value of the no cells blank to
zero. Differences in drug sensitivity of the respective cell lines were
determined from at least four independent experiments with
continuous drug exposure and are reported as the concentration
required to suppress proliferation by 50% (IC50).
In addition, one member of each drug class was tested for cyto-
toxic effects by means of colony forming assay and trypan blue
exclusion assay. Clonogenic survival in response to drug treatment
was performed by plating 1000 cells in 60 mm cell culture dishes.
After 24 h, the drug was added, followed by incubation for 6 days
at 378C in a humidiﬁed atmosphere containing 5% carbon dioxide.
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Figure 1 Antiproliferative effect to a continuous exposure to cisplatin,
oxaliplatin, doxorubicin, etoposide, docetaxel, and 5-ﬂuorouracil for
Pms2
+/+/p53
7/7 and Pms2
7/7/p53
7/7 cells as determined by the
MTT-assay. Each point represents the mean+s.d. of at least four indepen-
dent experiments.
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Figure 2 Clonogenic survival curves in response to a continuous expo-
sure to cisplatin, doxorubicin, docetaxel, and 5-ﬂuorouracil for the Pms2
+/
+/p53
7/7 and the Pms2
7/7/p53
7/7 cell lines. Each point represents the
mean+s.d. of at least four independent experiments.
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Giemsa. Colonies of at least 50 cells were scored visually. Each
experiment was performed a minimum of four times using tripli-
cate cultures for each drug concentration. The logarithm of relative
colony formation was plotted against the concentration of the
drug. The IC50 was estimated by linear interpolation of the loga-
rithmic transformed relative plating efﬁciencies. For trypan blue
exclusion assay, cells were grown to 60% conﬂuence and incubated
with or without the drug for 24 h, 48 h or 72 h. At the time points
indicated, ﬂoating and adherent cells were collected. Cells were
then incubated with trypan blue solution at 0.1% ﬁnal concentra-
tion for 1 min, and the number of trypan blue-positive and
-negative cells was determined using a haematocytometer.
TUNEL apoptosis assay
Cells were grown to 70% conﬂuence in 60 mm dishes in triplicate
cultures and then treated with 5 mM cisplatin. Adherent and ﬂoat-
ing cells were collected at the time points indicated and washed in
PBS. Cells were then ﬁxed by dropwise addition of ice-cold 70%
ethanol. Samples were stored at 48C until further use. Samples
were washed twice with PBS and resuspended in the TUNEL
reaction mixture and incubated at 378C for 2 h, according to the
manufacturer’s protocol (Roche Molecular Biochemicals, Basel,
Switzerland). Cells were analysed by ﬂow cytometry (EPICS ELITE,
Beckmann-Coulter, Hialeah, FL, USA).
Cell cycle analysis
Cells were grown to 70% conﬂuence in 60 mm dishes in triplicate
cultures and then incubated with or without cisplatin (1.0 mM).
This drug concentration induces about a 70% growth inhibition
of Pms2-deﬁcient cells in the MTT-assay and about a 95% reduc-
tion of clonogenic survival. Cells were then harvested by brief
trypsinisation and washed once in ice-cold PBS. The pellet was
resuspended in 200 ml PBS and cells were ﬁxed by dropwise addi-
tion of 4 ml ice-cold 70% ethanol and then stored at 48C until use.
After removing ethanol by centrifugation at 30006g and washing
twice in PBS, cells were stained in 1 ml of propidium iodide stain-
ing solution (50 mgm l
71 propidium iodide and 100 U ml
71
RNAse A in PBS) by incubation at room temperature for 60 min
in the dark and then washed once in PBS containing 0.2% BSA.
Samples were analysed for their DNA content by ﬂow cytometry
(EPICS ELITE, Beckmann-Coulter, Hialeah, FL, USA), and the
percentage of cells in each phase was determined using the Multi-
Cycle for Windows Software (Phoenix Flow Systems, San Diego,
CA, USA).
Statistical analysis
Mean+s.d. values were calculated for all data sets. The two-sided
paired t test was used to compare the effects of loss of Pms2 func-
tion on drug sensitivity. P50.05 was considered to be a statistically
signiﬁcant difference.
RESULTS
Growth inhibition of Pms2
+/+/p53
7/7 and Pms2
7/7/
p53
7/7 cells after treatment with anticancer agents
We addressed the question as to whether the concomitant loss of
Pms2 function in p53-deﬁcient cells is associated with changes in
sensitivity to a panel of clinically relevant anticancer agents. The
presence or absence of p53 and Pms2 in the respective cell lines
was veriﬁed by immunoblot analysis.
The antiproliferative effect of the platinum compounds cisplatin
and oxaliplatin, the topoisomerase II poisons doxorubicin, mitox-
antrone and etoposide, the taxanes docetaxel and paclitaxel, and
the antimetabolites 5-ﬂuorouracil and gemcitabine was tested in
cell lines proﬁcient or deﬁcient in Pms2 in a setting of p53 nulli-
zygosity. Figure 1 shows the antiproliferative effect to a continuous
exposure to cisplatin, oxaliplatin, doxorubicin, etoposide, docetaxel
and 5-ﬂuorouracil for Pms2
+/+/p53
7/7 and Pms2
7/7/p53
7/7 cells
as determined by the MTT-assay. The Pms2-deﬁcient Pms2
7/7/
p53
7/7 cells were 6.4-fold more sensitive to cisplatin
(0.7+0.3 mM vs 4.7+0.6 mM, P=0.0002), 2.5-fold more sensitive
to oxaliplatin (1.4+0.2 mM vs 3.5+1.1 mM, P=0.03), 5.3-fold more
sensitive to doxorubicin (13.9+2.2 nM vs 73.4+18.8 nM,
P=0.002), 3.0-fold more sensitive to mitoxantrone (2.7+0.8 nM
vs 8.1+1.8 nM, P=0.005), 6.1-fold more sensitive to etoposide
(17+3n M vs 105+30 nM, P=0.01), 4.8-fold more sensitive to
docetaxel (13+2n M vs 64+13 nM, P=0.0005), 4.3-fold more
sensitive to paclitaxel (15+4n M vs 66+14 nM, P=0.004), and
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Figure 3 Sensitivity to cell kill of Pms2
7/7/p53
7/7 (open ﬁeld)
and Pms2
+/+/p53
7/7 (closed ﬁeld) cells in response to cisplatin (3 mM),
doxorubicin (50 nM) or 5-ﬂuorouracil (5 mM) as a function of time deter-
mined by trypan blue exclusion. Each point represents the mean+s.d. of
at least four independent experiments.
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Figure 4 Representative cell cycle phase distribution proﬁle of the DNA content for Pms2
+/+/p53
7/7 cells (left panel) and Pms2
7/7/p53
7/7 cells (right
panel) as a function of time (0 h, 24 h, 48 h, 72 h) in response to treatment with 1.0 mM cisplatin. 2N represent cells accumulated in G1, 4N represent cells
accumulated in G2/M.
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P=0.001) as compared to the Pms2
+/+/p53
7/7 cells. In contrast, no
difference in sensitivity was found for 5-ﬂuorouracil (1.5+0.2 mM
vs 1.7+0.6 mM, P=0.43). Thus, our data indicate that the concomi-
tant loss of Pms2 in p53-deﬁcient cells results in a hypersensitivity
to platinum compounds, topoisomerase II poisons, taxanes, and
gemcitabine.
Clonogenic cell survival and trypan blue exclusion assays
Colorimetry-based short-term cytotoxicity assays such as the
MTT-assay may underestimate overall cell killing owing to the
notion that cells may not die immediately after treatment but
may instead remain in a transient state of arrest for several days
prior to dying (Brown and Wouters, 1999). Therefore, the clono-
genic assay was performed for one member of each drug class in
addition to the MTT-assay. Figure 2 shows the survival curves for
the Pms2-proﬁcient Pms2
+/+/p53
7/7 cell line as well as the
repair-deﬁcient Pms2
7/7/p53
7/7 cell line as a function of drug
concentration. In comparison to the Pms2
+/+/p53
7/7 cell line
the Pms2-deﬁcient Pms2
7/7/p53
7/7 cell line was 1.6-fold more
sensitive to cisplatin (0.68+0.10 mM vs 0.41+0.07 mM, P=0.002),
1.7-fold more sensitive to doxorubicin (12.1+1.4 nM vs
7.3+0.4 nM, P=0.004) and 1.8-fold more sensitive to docetaxel
(7.5+1.0 nM vs 4.0+0.2 nM, P=0.005). In contrast, no difference
in sensitivity was observed in response to 5-ﬂuorouracil
(0.57+0.06 mM vs 0.63+0.07 mM, P=0.25). Thus, the clonogenic
survival data support the results observed in the MTT-assay,
indicating that loss of Pms2 function in p53-deﬁcient cells
decreases clonogenic survival to these agents.
The trypan blue exclusion assay demonstrates that Pms2-deﬁ-
cient cells have a substantially higher percentage of trypan blue-
stained cells than Pms2-proﬁcient cells in response to equi-antipro-
liferative doses (i.e. doses that inhibited proliferation by 90% in
Pms2-deﬁcient cells) of doxorubicin (50 nM) or cisplatin (3 mM)
at each time point after treatment (Figure 3). This effect, however,
is not observed in response to 5-ﬂuorouracil (5 mM). These data
indicate that Pms2 deﬁciency reduces the threshold for cell kill
to doxorubicin and to cisplatin, but not to 5-ﬂuorouracil. Thus,
the higher sensitivity to cell kill of Pms2-deﬁcient cells to doxoru-
bicin or cisplatin conﬁrms the increased antiproliferative effect and
the decreased clonogenic survival of these cells to these agents.
Pms2-deﬁciency and cisplatin-induced apoptosis
Using cisplatin as a representative of compounds that display
hypersensitivity in clonogenic survival as well as in proliferation
inhibition, the TUNEL apoptosis assay was performed to determine
whether the increased sensitivity to cisplatin due to loss of Pms2
function was accompanied by increased apoptosis. Treatment with
5 mM cisplatin, which inhibited growth of Pms2-deﬁcient cells by
more than 95%, produced more apoptotic Pms2
7/7/p53
7/7 cells
than Pms2
+/+/p53
7/7cells. The respective values were 37+5% vs
5+1% at 30 h after cisplatin treatment and 43+4% vs 20+14%
at 60 h after treatment. These results indicate that the hypersensi-
tivity to the cytotoxic effect of cisplatin in Pms2-deﬁcient cells is
associated with increased apoptosis.
Cell cycle analysis of Pms2
+/+/p53
7/7 and
Pms2
7/7/p53
7/7 cells after treatment with cisplatin
The question was addressed as to whether the increased sensitivity
to, for instance, cisplatin in p53-deﬁcient cells is accompanied by
alterations in triggering cell cycle checkpoint activation. Cisplatin
has been shown to be a potent inducer of MMR-dependent
G2/M arrest (Brown et al, 1997). Figure 4 shows that 1 mM
cisplatin, which inhibited growth of Pms2-deﬁcient cells by 70%
in the MTT-assay, resulted in response to cisplatin in a sustained
accumulation at the G2/M transition of Pms2-proﬁcient and
-deﬁcient cells. The data demonstrate that both Pms2-proﬁcient
and -deﬁcient cells retain the ability to arrest at the G2/M
upon cisplatin treatment. Thus, the observed hypersensitivity in
Pms2-deﬁcient cells seems not to be accompanied by alterations
in the characteristic changes in cell cycle distribution proﬁle
induced by drug treatment.
DISCUSSION
The present study indicates that p53-null mouse ﬁbroblasts are
rendered hypersensitive to cell killing in response to platinum
compounds, topoisomerase II poisons, taxanes and the antimetabo-
lite gemcitabine by the concomitant loss of Pms2 function, and
that both Pms2-deﬁcient and -proﬁcient cells retain the ability to
arrest at G2/M upon cisplatin treatment. This observation is impor-
tant for several reasons: First, it identiﬁes PMS2 as another putative
protective mediator of cell survival in p53-deﬁcient cells, and it
thus expands on the previous ﬁnding reporting increased sensitivity
to cisplatin by the concomitant loss of MLH1 function (Vikhans-
kaya et al, 1999; Lin et al, 2001). Second, it identiﬁes, in
addition to the platinum compounds, two other clinically impor-
tant classes of anticancer agents that result in hypersensitivity in
p53-deﬁcient cells by the additional loss of MMR. Third, it further
supports the notion that MMR proteins such as PMS2 or MLH1
(Vikhanskaya et al, 1999; Lin et al, 2001) modulate protective
DNA damage response pathways independently of p53 function.
This ﬁnding supports the concept of a novel role of MMR, in addi-
tion to mediating drug-induced cytotoxicity (Fink et al, 1998;
Fedier et al, 2001), as a positive modulator of cell survival after
DNA damage. A precedent for this hypothesis has already been
found as it has been reported that MLH1-deﬁciency is associated
with hypersensitivity to mitomycin C in p53-proﬁcient cells
(Fiumicino et al, 2000). Fourth, the observed hypersensitivity of
Pms2-deﬁcient cells seems to be independent of the cell cycle
and seems to be due to increased apoptosis. The observed p53-
independence of cytotoxicity goes along with the previous observa-
tion that MMR can trigger apoptosis in a p53-independent
pathway (Zeng et al, 2000).
Mutations that disable p53 are frequently found in human
cancers (Hollstein et al, 1991), often in association with tumour
progression or high grade malignancy (Carder et al, 1993). There-
fore, much effort has gone into determining the effects of p53
inactivation on the response of cancer cells to therapeutic agents.
The results vary with the cell line under study and the experimental
set-up, and thus both decreased and increased sensitivities have
been observed in different model systems (Blandino et al, 1999;
Bunz et al, 1999). Recently, it has been reported that loss of
MLH1 is associated with a hypersensitivity to cisplatin in p53-deﬁ-
cient cells in the HCT116 model (Vikhanskaya et al, 1999; Lin et al,
2001). However, the repair-deﬁcient member of these cell lines was
not truly isogenic since in order to restore MMR activity a whole
copy of chromosome 3 carrying a wild-type copy of MLH1 was
inserted into the HCT116 cells (Koi et al, 1994). The present study
uses isogenic primary ﬁbroblasts established from E1A/Ha-Ras-
transfected knockout mice. These cells are genetically well deﬁned
and therefore constitute a more meaningful test system than
cancer-derived cell lines, not only because they are truly isogenic
but also because the cancer-derived cells are likely to contain a
number of other accumulated mutations and abnormalities that
could inﬂuence response to anticancer agents. It is unlikely that
the hypersensitivity seen in the Pms2
7/7/p53
7/7 cells was due
to the experimental set-up rather than being caused by the lack
of Pms2 function, because the increased sensitivity was also
observed, though to a lesser extent, in the clonogenic survival assay
and in the trypan blue exclusion assay. This observation indicates
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Chemosensitivity in p53-deficient cells
A Fedier et al
1031
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(9), 1027–1033that the increased sensitivity to the platinum compounds, the
topoisomerase II poisons and the taxanes arises through enhanced
cell killing rather than only through decreased proliferation ability.
The increased cell killing by cisplatin in cells lacking Pms2 is paral-
leled by increased apoptosis.
The mechanism by which the MMR proteins may inﬂuence
damage response is not yet fully understood. One hypothesis
proposes that the MMR proteins recognise base damage and
initiate a cycle of futile repair, leading to gaps and breaks that
may ultimately signal apoptosis (Vaisman et al, 1998). It is also
possible that the recognition of damage by the MMR proteins
directly initiate a signal transduction pathway (Fink et al,
1998). Direct evidence supporting the latter hypothesis includes
a requirement for MLH1 function in cisplatin induction of c-
abl kinase activity (Nehme ￿ et al, 1997) and of p73 accumulation
(Gong et al, 1999).
An increased cytotoxic effect due to loss of Pms2 was observed
in p53-deﬁcient cells to a panel of drugs that have different
modes of action and introducing different types of damage. The
molecular basis for the putative protective role of MMR in the
p53-independent response to platinum compounds, topoisomerase
II poisons and to taxanes is not yet clear. Loss of either Pms2 or
MLH1 (Vikhanskaya et al, 1999; Lin et al, 2001) results in p53-
deﬁcient cells in hypersensitivity to cisplatin, whereas loss of
MLH1 or PMS2 results in p53-proﬁcent cells in resistance to
cisplatin (Aebi et al, 1996; Fink et al, 1997). Likewise, cell kill
by topoisomerase II poisons, but not by taxanes, has been
reported to be affected by loss of MMR (Fedier et al, 2001; Lin
et al, 2001), indicating that MMR-dependent damage response
is, at least partially, modulated by p53. Indeed, cross talks between
MMR- and p53-dependent pathways have been reported (Duckett
et al, 1999; Wu et al, 1999). Cells defective in p53 function retain
the ability to mediate apoptosis by a p73-dependent pathway
(Gong et al, 1999), which may be modulated by certain MMR
proteins. It is possible that PMS2 and MLH1 protect cells from
excessive cell death by counteracting p73-mediated apoptosis in
a MMR-dependent manner upon DNA damage introduced by
cisplatin or topoisomerase II poisons. In a p53-independent path-
way PMS2 may, as in the case of cisplatin, decrease adduct
tolerance and damage accumulation on this basis. Oxaliplatin
and cisplatin produce different types of DNA damage and thus
have been shown to display a differential response in MMR-deﬁ-
cient cells proﬁcient for p53 (Fink et al, 1996). Our data thus
suggest a role for PMS2 in a DNA damage response pathway in
addition to that in MMR. However, the possibility can not be
excluded that p53 modulates oxaliplatin damage differently from
that of cisplatin damage. Likewise, PMS2 may modulate the efﬁ-
cacy of the repair machinery to process stalled replication forks
arisen by blocked DNA-topoisomerase intermediates and gaps
introduced by the chain-terminating antimetabolite gemcitabine.
Additional loss of PMS2 thus abolishes the damage removal activ-
ity, giving rise to excessive DNA damage and cytotoxicity. The
ﬁnding that MMR-deﬁciency does not alter 5-ﬂuorouracil cyto-
toxicity in a p53-deﬁcient setting may be of clinical interest for
the treatment of colorectal cancer, despite the previously reported
in vitro association of MMR with resistance to 5-ﬂuorouracil in
p53-proﬁcient cells (Carethers et al, 1999).
p53 either mediates growth arrest, both in G1 or G2 phases of
the cell cycle, or directs cells to apoptosis. These two cellular deci-
sions are distinctive end points of p53 induction, depending on the
cellular context and the type of DNA damage. The present study
demonstrates that both Pms2-proﬁcient and -deﬁcient cells retain
the ability to arrest at the G2/M upon cisplatin treatment and that
loss of Pms2 is not accompanied by substantial alterations in the
characteristic changes in cell cycle distribution. A similar result
has also been reported in p53-deﬁcient cells after loss of Msh2
(Strathdee et al, 2001) or MLH1 (Lin et al, 2001). Therefore, it
seems unlikely that MMR is a major trigger for a G2/M arrest in
cells that lack functional p53.
The feature that p53 and MMR proteins modulate cellular
responses upon DNA damage and the availability of genetically
engineered human and murine cells present a potential means to
develop strategies to circumvent the reduced responsiveness by
re-sensitising or by hypersensitising p53-mutant tumours to thera-
peutic regimens. Candidate approaches include the restoration of
the wild-type p53 function, the activation of cytotoxic pathways
that operate independently of p53, or the concurrent disruption
of genes implicated in DNA damage response pathways (Mcgill
and Fisher, 1999).
Since both, MMR and p53 status affect the mechanism of cyto-
toxicity, the genotype-based predictions may require that the MMR
status as well as the p53 status of the tumour are taken into
account. In summary, the present data show that p53-deﬁcient cells
are sensitised to the platinum compounds, the topoisomerase II
poisons and the taxanes by the concurrent loss of Pms2 function.
Although PMS2 mutations or mutations in both PMS2 and p53 are
not frequently found in human cancers and thus may be of minor
clinical importance, our study may nevertheless contribute to
fostering the concept that tumour-targeted functional inhibition
of PMS2 may be an adjunct to chemotherapy in the treatment
of tumours unresponsive to therapeutic regimens due to mutations
in the p53 gene.
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